To include your compound in the COVID-19 Resource Center, submit it here.

Poly-nating the HCV space

The gaggle of companies developing oral polymerase inhibitors to treat HCV just got a little bigger, as Roche has signed with Pharmasset Inc. to develop PSI 6130, an oral nucleoside polymerase inhibitor in late preclinical development.

According to Abel De

Read the full 400 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE